Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHPA defends plant imports from law

This article was originally published in The Tan Sheet

Executive Summary

The Animal and Plant Health Inspection Service of the Department of Agriculture should exempt plants imported for use in foods, drugs and cosmetics from the importation disclosure requirements in the Lacey Act, the American Herbal Products Association says in comments submitted Dec. 8. The Lacey Act is intended to prevent illegal timber trade, AHPA says, but could affect herbal imports due to language in the 2008 federal farm subsidy programs reauthorization (1"The Tan Sheet" May 19, 2008, p. 11). AHPA is concerned the act's expanded jurisdiction over plants, plant parts and plant products "will result in filing of ... unnecessary and largely redundant information for plants that are neither timber nor derived from timber," President Michael McGuffin says

You may also be interested in...



Farm Bill Grows Herbal Crop Support, But No Vitamins In Food Stamp Program

Congress added financial support for herbals and other specialty crops to the federal farm subsidy programs reauthorization, but omitted multivitamins from food stamp coverage for the second time

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel